HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Second-generation drugs called into first-line therapy for CML
-
- Cancer incidence, deaths expected to double by 2030 without preventive measures
- Everolimus improved PFS in neuroendocrine tumors
- FDA approves rituximab for advanced follicular lymphoma
- FOLFOX plus cetuximab produced objective response rate of 77% in cardia, esophageal cancer
- GIDEON: Oncologists give lower doses, shorter duration of sorafenib for hepatocellular carcinoma
- RecQ1 A159C genotype predictive for some resectable pancreatic cancers
- S-1 might have potential, PEP02 may not
- Weigh risk vs. benefit when using bevacizumab combined with chemotherapy Andrew H. Ko, MD
-
- Evolving insight into personalized therapy requires changes in health care delivery, reimbursement Stephen Y. Chui, MD
- Two challenging cases pose treatment questions William Wood, MD
- Antifibrinolytic drug may help prevent trauma patient deaths from blood loss
- BIOSTATE produced favorable hemostatic efficiency in 90% of surgical bleeding events
- Dutch MRI Screening Study: Ongoing differences observed between BRCA1 and BRCA2 tumors
- First-line hydroxyurea may be effective in polycythemia vera, essential thrombocythemia
- Immunohistochemical analysis may not benefit negative sentinel nodes in breast cancer
- Prognostic factors identified for locally advanced NSCLC
-
- Third-trimester screening may detect previously undetected red blood cell antibodies
- Triplex nucleic acid testing detected HBV, HIV, HCV before seroconversion
- Two biomarkers of splenic function in sickle cell anemia may correlate with liver-spleen scan
- Unrealistic optimism created ethical dilemma in early-phase cancer trials
- FOLFOX plus cetuximab produced ORR of 77% in cardia, esophageal cancer
- Denosumab in the prevention of skeletal-related events Lisa K. Lohr, PharmD, BCPS, BCOP